Nivolumab and DAY101 for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults
Latest Information Update: 21 Dec 2024
At a glance
- Drugs Nivolumab (Primary) ; Tovorafenib (Primary)
- Indications Craniopharyngioma
- Focus Therapeutic Use
- Acronyms PNOC029
- 12 Sep 2022 Planned initiation date changed from 1 Sep 2022 to 13 Sep 2022.
- 12 Sep 2022 Status changed from not yet recruiting to recruiting.
- 27 Jul 2022 New trial record